Abingworth Management, the life sciences investment group, has appointed David Pinniger, CFA as a principal, analyst.
He will focus on evaluating new and existing investment opportunities in public life science companies in Abingworth portfolios, including providing support to the recently launched Abingworth BioEquities Fund (ABE). ABE is Abingworth’s first fund dedicated solely to investments in quoted stocks.
Pinniger joined Abingworth from Morgan Stanley where he was a sell-side equity analyst in the European Healthcare team responsible for investment research in listed biotechnology companies. He has a first class degree in Human Sciences from Oxford University and was awarded CFA charter holder status in August 2003. Pinniger will be based at the company’s headquarters in London.
“We are delighted to welcome David to the team,” said Dr Joe Anderson, partner and portfolio manager. “He brings proven equity research skills to Abingworth at a time when we are growing our new fund.”